更正：B7-H3 CAR-T 细胞清除肝内胆管癌并诱导持久应答
Correction: B7-H3 CAR T cells eradicate intrahepatic cholangiocarcinoma and induce durable response.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
不可切除胆管癌的靶向治疗和免疫治疗
英文原题：Targeted therapies and immunotherapies for unresectable cholangiocarcinoma.
查看英文原题
Targeted therapies and immunotherapies for unresectable cholangiocarcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
胆管癌（CCA）是一种致死性恶性肿瘤，发病率持续上升且预后较差。由于大多数CCA病例确诊时已处于晚期，包括化疗、放疗、靶向治疗和免疫治疗在内的全身治疗在不可切除CCA的管理中起着至关重要的作用。近年来靶向治疗和免疫治疗的进展为不可切除CCA的临床管理带来了更多选择。本综述阐述了不可切除CCA靶向治疗和免疫治疗的进展，总结了关键临床试验，并描述了不同药物的疗效和安全性，这可能有助于进一步推动不可切除CCA临床治疗中的精准化和个体化。
展开英文摘要原文
Cholangiocarcinoma (CCA) is a fatal malignancy with steadily increasing incidence and poor prognosis. Since most CCA cases are diagnosed at an advanced stage, systemic therapies, including chemotherapy, radiotherapy, targeted therapy, and immunotherapy, play a crucial role in the management of unresectable CCA.
The recent advances in targeted therapies and immunotherapies brought more options in the clinical management of unresectable CCA. This review depicts the advances of targeted therapies and immunotherapies for unresectable CCA, summarizes crucial clinical trials, and describes the efficacy and safety of different drugs, which may help further develop precision and individualization in the clinical treatment of unresectable CCA.
论文信息
- 作者
- Xue S、Jiang W、Ma J、Xu H、Wang Y、Lu W、Shentu D、Cui J
- 单位
- Department of Oncology and State Key Laboratory of Systems Medicine for Cancer of Shanghai Cancer Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China.China
- 文献类型
- 综述
- 期刊
- Chinese medical journal2025 Aug 20
- 原文标识
- PubMed 40693603 · DOI 10.1097/CM9.0000000000003705
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →